SLC5A2 and type 2 diabetes mellitus: The results of this study suggest that the addition of SGLT2 inhibitors to BBT may also offer a relatively safe and effective approach to achieving target blood glucose levels in hospitalised patients with type 2 diabetes mellitus and hyperglycaemia.